Patents Examined by Zachary S Skelding
-
Patent number: 11987613Abstract: Provided are isolated TCRs, TCR-like molecules, and portions thereof that bind to phosphopeptide-HLA-A2 complexes. The isolated TCRs, TCR-like molecules, or portions are optionally soluble TCRs, TCR-like molecules, or portions. Also provided are isolated nucleic acids encoding the disclosed TCRs, TCR-like molecules, or portions; host cells that contain the disclosed TCRs, TCR-like molecules, or portions; pharmaceutical compositions that include the disclosed TCRs, TCR-like molecules, portions, nucleic acids, and/or T cells; kits; and methods of using the same.Type: GrantFiled: May 18, 2020Date of Patent: May 21, 2024Assignee: University of Virginia Patent FoundationInventors: Angela L. Ambakhutwala, Victor H. Engelhard, Kara L. Cummings, Rebecca C. Obeng
-
Patent number: 11987616Abstract: The invention provides, in various embodiments, polypeptides (e.g., camelid antibodies and antigen binding fragments thereof) that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).Type: GrantFiled: February 15, 2023Date of Patent: May 21, 2024Assignee: Flagship Pioneering Innovations VI, LLCInventors: Gevorg Grigoryan, John Ingraham
-
Patent number: 11981739Abstract: The present invention relates to a chimeric antigen receptor (CAR) specific for an IL-23 receptor, and to a nucleic acid encoding the same. The present invention further relates to a T cell expressing said CAR, and to the use thereof for treating an autoimmune and/or inflammatory disease or disorder.Type: GrantFiled: April 15, 2019Date of Patent: May 14, 2024Assignee: SANGAMO THERAPEUTICS FRANCEInventors: Tobias Abel, Julie Gertner-Dardenne, François Meyer
-
Patent number: 11981743Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: April 29, 2020Date of Patent: May 14, 2024Assignees: Biocon Limited, CENTRO DE INMUNOLOGIA MOLECULARInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 11981749Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from TMA associated with hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.Type: GrantFiled: August 4, 2020Date of Patent: May 14, 2024Assignees: OMEROS CORPORATION, UNIVERSITY OF LEICESTERInventors: Gregory A. Demopulos, Thomas A. Dudler, Hans-Wilhelm Schwaeble
-
Patent number: 11970540Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.Type: GrantFiled: June 20, 2018Date of Patent: April 30, 2024Assignee: TENEOBIO, INC.Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
-
Patent number: 11970535Abstract: This invention relates to the use of KIR3DL2-targeting agents for the treatment of CTCL. The invention provides advantageous treatment regimens using anti-KIR3DL2 antibodies for the treatment of CTCL, notably in first-line CTCL.Type: GrantFiled: December 8, 2020Date of Patent: April 30, 2024Assignee: INNATE PHARMAInventors: Carine Paturel, Helene Sicard
-
Patent number: 11965014Abstract: The present invention relates to a novel chimeric antigen receptor comprising a CD99 region which participates in immune synapse stabilization as a backbone of the chimeric antigen receptor, an immune cell comprising the same, and the uses thereof. CD99-based CAR-T cells are capable of forming very stable immune synapses with tumor cells compared to conventional backbone-based CAR-T cells and can exhibit improved tumor therapeutic efficiency, so they can be useful for immune cell therapy for the treatment of cancer.Type: GrantFiled: July 28, 2021Date of Patent: April 23, 2024Assignee: TICAROS CO., LTD.Inventors: Kyungho Choi, Eun-Young Choi, Giri Nam, Hyung-Bae Park, Ji-Eun Lee, Hye-Ran Yeon
-
Patent number: 11965012Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.Type: GrantFiled: December 21, 2022Date of Patent: April 23, 2024Assignee: TCR2 THERAPEUTICS INC.Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister
-
Patent number: 11952428Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: GrantFiled: February 17, 2023Date of Patent: April 9, 2024Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Patent number: 11945854Abstract: Disclosed are T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The description further relates to peptides, proteins, nucleic acids, cells for use in immunotherapeutic methods, the immunotherapy of cancer, and tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: December 17, 2020Date of Patent: April 2, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Dominik Maurer, Sebastian Bunk, Leonie Alten
-
Patent number: 11945867Abstract: The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.Type: GrantFiled: December 21, 2019Date of Patent: April 2, 2024Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Shimobi Onuoha, Ana Margarida Neves, Mathieu Ferrari, Paul Maciocia
-
Patent number: 11939572Abstract: The invention relates to a chimeric antigen-receptor polypeptide heterodimer comprising two polypeptides, wherein the first contains an extracellular part of the major histocompatibility complex I alpha chain and the second contains a 32-microglobulin domain, or the first contains an extracellular part of the major histocompatibility complex II alpha chain and the second contains a major histocompatibility complex II beta chain. One of the polypeptides further contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor alpha chain and the other one contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor beta chain, and additionally an antigen-peptide covalently linked to said extracellular MHC domain. The invention further relates to a method for the identification of a TCR recognizable peptide sequence making use of the heterodimer of the invention.Type: GrantFiled: November 13, 2020Date of Patent: March 26, 2024Assignee: ETH ZürichInventors: Jan Kisielow, Franz-Josef Obermair, Manfred Kopf
-
Patent number: 11939376Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.Type: GrantFiled: August 21, 2020Date of Patent: March 26, 2024Assignee: Immatics Biotechnology GmbHInventors: Leonie Alten, Dominik Maurer, Steffen Walter, Sebastian Bunk
-
Patent number: 11939375Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: February 22, 2021Date of Patent: March 26, 2024Assignee: Janssen Biotech, Inc.Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya Orlovsky, Robert Rauchenberger, Raymond Sweet
-
Patent number: 11939389Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.Type: GrantFiled: February 17, 2023Date of Patent: March 26, 2024Assignee: Novartis AGInventors: Aida Abujoub, John Blankenship, Dexiu Bu, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Chonghui Zhang
-
Patent number: 11932689Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.Type: GrantFiled: December 17, 2020Date of Patent: March 19, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Felix Unverdorben, Sebastian Bunk, Martin Hofmann, Dominik Maurer, Meike Hutt, Claudia Wagner, Leonie Alten
-
Patent number: 11925684Abstract: The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific antibodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.Type: GrantFiled: August 29, 2018Date of Patent: March 12, 2024Assignee: AMGEN RESEARCH (MUNICH) GMBHInventors: Roman Kischel, Tobias Raum, Bernd Schlereth, Doris Rau, Ronny Cierpka, Peter Kufer
-
Patent number: 11896621Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a human subject suffering from graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with a hematopoietic stem cell transplant. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.Type: GrantFiled: April 9, 2021Date of Patent: February 13, 2024Assignees: Omeros Corporation, University of LeicesterInventors: Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
-
Patent number: 11884742Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.Type: GrantFiled: October 2, 2019Date of Patent: January 30, 2024Assignees: Omeros Corporation, University of LeicesterInventors: Hans-Wilhelm Schwaeble, Clark E. Tedford, James B. Parent, Thomas Dudler, Gregory A. Demopulos